AXEVIL Capital

Cellares Stock Price, Valuation & IPO

Private company — Cellares is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.

Status source: AXEVIL investment team

$17.48 per share (AXEVIL consensus estimate)

Source: AXEVIL consensus of recent secondary transactions · as of 10 November 2026

Total raised: ~$682M

Data last updated: 10 November 2026

About Cellares

Automated manufacturing of cell therapies as a service: closed robotic Cell Shuttle systems run up to 16 batches at once, with up to 90% less labor per batch. It has raised about $682 million in total; its valuation has not been disclosed.

Cellares was founded in 2019 in South San Francisco by Fabian Gerlinghaus, Omar Kurdi and Alex Pesch, all alumni of Synthego. Cell therapies for cancer are still made by hand for each patient: a commercial dose costs $503,000–$605,000 and takes three to six weeks to produce. Cellares developed Cell Shuttle, closed robotic systems that run up to 16 batches at once and up to 2,800 batches a year, and Cell Q, an automated quality control lab, and sells manufacturing as a service to drug developers, requiring up to 90% less labor and floor space. In April 2025 Cell Shuttle became the first to receive the FDA's Advanced Manufacturing Technology designation, and in 2026 the company joined the first cohort of the PreCheck program: seven companies out of about 80 applicants. It has raised about $682 million in total; the $327 million Series D was led by BlackRock and Eclipse.

  • Sector: Healthcare & Biotech
  • Headquarters: South San Francisco, USA
  • Founded: 2019

Key highlights

  1. Cabaletta Bio: from first patients to a 10-year agreement. For about three years the companies worked to transfer manufacturing of rese-cel, a CAR-T therapy for autoimmune diseases, to Cell Shuttle. In April 2026 the first two doses met all release criteria and were administered to patients, and two weeks later Cabaletta signed a 10-year commercial supply agreement.
  2. Taiwan and Korea: into Asia within a week. On September 16, 2026, Taiwan's GenomeFrontier agreed to evaluate transferring the virus-free process for its CAR-T therapy for lymphomas to Cell Shuttle. A week later, Seoul National University Hospital launched a stem cell project targeting a rare blood disease.
  3. Bristol Myers Squibb: exit from a $380 million agreement. In 2024 BMS reserved Cellares capacity in the U.S., Europe and Japan. In August 2026 the company terminated the agreement, saying Cell Shuttle did not meet the requirements for commercial Breyanzi; Cellares disputed that assessment.

Frequently asked questions

How can I buy Cellares stock before the IPO?

Not on a public exchange — Cellares is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.

What is the Cellares stock price?

A private company has no single official share price. AXEVIL's consensus estimate is $17.48 per share as of 10 November 2026.

What is Cellares's valuation (net worth)?

AXEVIL does not have a verified valuation for Cellares at the moment; it appears here once a priced round is on record.

When will Cellares IPO?

No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.

Is Cellares publicly traded?

No. Cellares is a private company and its shares are not listed on any public exchange.

Does Cellares have a stock symbol?

No. Cellares has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.

Similar companies

Risk disclosure

Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.

Full legal disclosures · All companies